Minovia Therapeutics Ltd. recently announced it has been granted two new US patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Therapy (MAT) platform.

The newly granted patents cover mitochondrial augmentation therapy for primary mitochondrial diseases and mitochondrial augmentation therapy for renal diseases, providing extended protection for Minovia’s core platform technology. Corresponding patents have also been granted in Europe and Japan, with additional applications pending in other major global jurisdictions.

US Patent No. 12,502,408 relates to Minovia’s proprietary mitochondrial augmentation technology for the treatment of primary mitochondrial diseases. The claims cover Minovia’s lead program, MNV-201, which consists of autologous hematopoietic stem cells enriched with placental-derived mitochondria. MNV-201 is currently being evaluated in clinical trials for Pearson Syndrome and other severe genetic mitochondrial disorders.

US Patent No. 12,329,781 relates to Minovia’s proprietary mitochondrial augmentation technology for the treatment of renal diseases, including renal tubulopathy, kidney insufficiency, and chronic kidney disease (CKD), broadening the potential therapeutic applications of the MAT platform beyond primary mitochondrial disorders.

“These new patent grants strengthen and protect Minovia’s intellectual property and underscore the versatility of our proprietary mitochondrial augmentation platform across multiple serious disease areas,” said Minovia Co-founder and CEO, Natalie Yivgi-Ohana, PhD. “Securing protection for both our lead mitochondrial disease program and our expanding renal disease applications supports our long-term strategy to develop transformative therapies to effectively treat patients with high unmet medical needs.”

Minovia’s MAT platform is designed to restore mitochondrial function by augmenting patient-derived cells with healthy mitochondria, addressing the underlying bioenergetic deficiencies that drive disease pathology. The company continues to advance its clinical and preclinical programs while expanding its global patent estate to support future development and partnering opportunities.

The Company previously announced entry into a definitive business combination agreement (the Business Combination Agreement) with Launch One Acquisition Corp. (Nasdaq: LPAA, Launch One), a publicly traded special purpose acquisition company. Following the expected closing of the transaction contemplated by this Business Combination Agreement (the Business Combination), projected for the first half of 2026, the combined company will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol.

MNV-201 is a first-in-class cell therapy that uses Minovia’s proprietary Mitochondrial Augmentation Technology (MAT) to add healthy, energy-producing mitochondria into a patient’s own stem cells — aiming to restore organ function and improve health. In early-stage clinical studies, MAT has demonstrated a strong safety profile and signs of multi-system benefit in patients with Pearson Syndrome, including improvements in growth, muscle function, hematologic stability, and improved quality of life.

Minovia Therapeutics, chaired by John Cox, is a clinical-state biotechnology company working on treatments to replace dead or defective mitochondria with new healthy mitochondria, helping people with mitochondrial diseases and fighting aging. Minovia’s main treatment, MNV-201, is already being tested for Pearson Syndrome and Myelodysplastic Syndrome. Minovia is also developing ways to help people live longer, healthier lives. Based in Haifa, Israel, where it operates a GMP facility for mitochondrial drug substance and drug product manufacturing for clinical trials related to its therapy, Minovia is planning to expand operations to the US. For more information, visit www.minoviatx.com.